|
Multiphase Efficacy Study of venlafaxine ER to Treat Recurrent Depression Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Multiphase Efficacy Study of venlafaxine ER to Treat Recurrent Depression conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Multiphase Efficacy Study of venlafaxine ER to Treat Recurrent Depression Clinical research trials and Multiphase Efficacy Study of venlafaxine ER to Treat Recurrent Depression medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Multiphase Efficacy Study of venlafaxine ER to Treat Recurrent Depression. Multiphase Efficacy Study of venlafaxine ER to Treat Recurrent Depression Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Multiphase Efficacy Study of venlafaxine ER to Treat Recurrent Depression clinical trial. Participants frequently get the best healthcare available for their Multiphase Efficacy Study of venlafaxine ER to Treat Recurrent Depression condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "M" Clinical Trials Conditions > Multiphase Efficacy Study of venlafaxine ER to Treat Recurrent Depression  Multiphase Efficacy Study of venlafaxine ER to Treat Recurrent Depression
Multiphase Efficacy Study of venlafaxine ER to Treat Recurrent Depression
For Condition: Depression
Status: No longer recruiting
Sponsor(s): Wyeth-Ayerst Research ,
Synopsis: The purpose of this study is to review the long-term comparative efficacy of venlafaxine ER in achieving and sustaining remission (wellness) in patients with recurrent major depression
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - Clinical diagnosis for recurrent major depression Exclusion Criteria - The patient has failed on an adequate trial of fluoxetine, venlafaxine or venlafaxine ER during the current episode of major depression or the patient is treatment-resistant - Known hypersensitivity to venlafaxine or fluoxetine - History or presence of clinically significant hepatic, cardiovascular or renal disease, or other serious medical disease, including history of seizure disorder - History or presence of bipolar disorder or eating disorder, or significant personality disorders or mental retardation (Axis II disorders) which would interfere with participation in the study - Patients diagnosed with panic disorder, obsessive compulsive disorder, generalized anxiety disorder, social phobia, PTSD within 6 months prior to screening, or current postpartum depression - History or presence of any psychotic disorder, including psychotic depression, or history or presence of any organic mental disorder - The patient has had a diagnosis of cancer in the past 3 years (excluding squamous or basal cell carcinoma) - The patient has dysphagia or difficulty swallowing tablets or capsules - Pregnant or breast-feeding women - The patient has any clinically significant condition that would, in the Investigator�s opinion, preclude study participation
Total Enrollment:
Location and Contact Information:
Islan Park Professional Center
Springfield, Oregon, 97477
United States
Synergy Clinical Research Center
San Diego, California, 92120
United States
University of Washington, Dept of Psychiatry, Center for Anxiety and Depression
Seattle, Washington, 98105
United States
Rush Presbyterian/St. Luke's Medical Center
Chicago, Illinois, 60612
United States
Rush-Presbyterian/St. Luke's Medical Center
Chicago, Illinois, 60612
United States
Weisler and Associates
Raleigh, North Carolina, 27612
United States
Pahl Brain Associates, P.C.
Oklahoma City, Oklahoma, 73118
United States
Pharmacology Research Institute
Los Alamitos, California, 90720
United States
Synergy Clinical Research Center
Chula Vista, California, 91910
United States
Pharmacology Research Institute
Northridge, California, 91324
United States
Birmingham Psychiatry Pharmaceutical Studies Inc.
Birmingham, Alabama, 35209
United States
Boca Raton Medical Research, Inc.
Boca Raton, Florida, 33433
United States
Emory University, Dept of Psychiatry and Behavioral Sciences
Atlanta, Georgia, 30329
United States
Lansdale Medical Group
Lansdale, Pennsylvania, 19446
United States
Virginia Commonwealth University
Richmond, Virginia, 23220
United States
North Coast Clinical Trials
Beachwood, Ohio, 44122
United States
Delaware Valley Research Associates, Inc.
Conshohocken, Pennsylvania, 19428
United States
Rhode Island Hospital, Mood Disorders Program
Providence, Rhode Island, 02903
United States
Institute for Health Studies
Okemos, Michigan, 48864
United States
Irving S. Kolin, M.D., P.A.
Winter Park, Florida, 32789
United States
Center for Emotional Fitness
Moorestown, New Jersey, 08057
United States
University of Texas Southwestern Medical Center, Dallas
Dallas, Texas, 75235
United States
Pharmacology Research Institute
Riverside, California, 92056
United States
University of Pittsburgh, Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania, 15213
United States
University of Texas Medical Branch, Dept of Psychiatry
Galveston, Texas, 77555
United States
Henry Lahmeyer, MD
Northfield, Illinois, 60083
United States
Community Clinical Research, Inc.
Austin, Texas, 78756
United States
University of MA Mental Health Care
Worcester, Massachusetts, 01605
United States
Pharmacology Research Clinic
Salt Lake City, Utah, 84107
United States
Stanford University School of Medicine
Stanford, California, 95305
United States
University of Arizona
Tucson, Arizona, 85724
United States
Rush-Presbyterian/St. Luke's Medical Center
Skokie, Illinois, 60076
United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37212
United States
Pharmacology Research Institute - Newport
Newport Beach, California, 92660
United States
University of New Mexico Health Science Center
Albuquerque, New Mexico, 87131
United States
University of Cincinnati
Cincinnati, Ohio, 45237
United States
Summit Research Network (Oregon)
Portland, Oregon, 97209
United States
University of Wisconsin, Dept of Psychiatry
Madison, Wisconsin, 53719
United States
Cornell Medical Center
New York City, New York, 10021
United States
R/D Clinical Research, Inc.
Lake Jackson, Texas, 77566
United States
Northbrooke Research Center
Brown Deer, Wisconsin, 53223
United States
Institute for Health Studies
Farmington Hills, Michigan, 78336
United States
Additional Information:
Study ID Numbers: 0600B-100469;
Study Start Date:
Record last reviewed: November 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00046020
Other Depression Studies:
1. Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
2. Sertraline Compared With Hypericum Perforatum (St. John's Wort) in Treating Mild to Moderate Depression in Patients With Cancer
3. Major depression and inflammatory risk markers for coronary heart disease
4. Evaluating "Health at Every Size"(HAES) as an Alternative Obesity Treatment Model
5. Effectiveness of Team Treatment of Depression in Primary Care
Related Studies:
Other Depression Clinical Trials
Other Tennessee Clinical Trials
Other Nashville Clinical Trials
Multiphase Efficacy Study of venlafaxine ER to Treat Recurrent Depression
|
|
|
|
|
|
|
|
